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Preface
This paper was inspired by my investigations into the cancer stem cell
hypothesis following a course in the molecular biology of cancer with Dr. Julia
Kirshner. Cancer is one of the greatest health burdens in the world, and it has
become clear in recent years that current therapies are not sufficient in reducing the
worldwide cancer burden. Contemporary findings in cell and cancer biology
illustrate the need for improvements of cancer treatments in order to reduce
instances of drug resistance, relapse, and toxicity that result from chemotherapy,
radiation, and surgery. The need to shift away from antediluvian cancer therapies is
dire.
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Abstract
Cancer, a leading cause of death in many developed countries, has become a
global health burden. Much of the drain on healthcare systems has resulted from the
high cost and ineffectiveness of conventional cancer treatments, which often lead to
cancer relapse or metastasis. The failures of chemotherapy, radiation, and surgery
have been elucidated by the cancer stem cell (CSC) hypothesis, which postulates
that a small percentage of tumor cells drive tumorigenesis. These cells can sustain
cancer through their capacity to self-renew and differentiate into specialized tumor
cell types, similar to how healthy stem cells maintain healthy tissues. Conventional
cancer treatments target the “bulk,” non-CSC tumor cells, leaving behind drugresistant cancer stem cells. Theoretically, treatments that eradicate entire
populations of cancer stem cells prevent drug resistance, relapse, and metastasis of
cancer, leading to more favorable outcomes for patients. Currently, therapies
targeting CSCs are being explored both in the lab and in clinical trials, many of which
show promise as effective drugs to be used in future widespread practice. Drugs
that have the ability to destroy CSCs eliminate many of the side side effects and
reduce the toxicity of current cancer therapies, if they are formulated to be CSCspecific. The CSC hypothesis has widespread global health implications, presenting a
way to reduce the cost of cancer treatment and to prolong and improve lives of
cancer patients.
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Introduction
Cancer is the second leading cause of mortality in the United States,
accounting for one in every four deaths, and killing more people than car accidents,
suicide, and communicable diseases combined. While cancer death rates have been
declining in the recent years due to improved prevention, early detection, and
pharmaceutical innovation, a vast number of mortalities occur because of treatment
failures. Currently, chemotherapy, radiation, and surgery are the top three cancer
treatment methods, which have been utilized in common practice for several
decades. Cancer chemotherapy treatments have continued to evolve since the
1940s, after German use of chemical warfare agents prompted research on their
therapeutic applications.1 In 1965, combination chemotherapy was introduced into
practice to combat cancer cell drug resistance; today, combining different
chemotherapy drugs has become a common practice for oncologists.
Chemotherapy, radiation, and surgery are still the three most common
cancer treatments. New chemotherapy drugs and surgical procedures continue to
be discovered, increasing survival rates and quality of life for patients. However,
drug resistance, relapse, and drug toxicity are common problems that
chemotherapy either fails to address or causes. Prognosis for some types of cancer
is generally very poor, despite improvements in treatments; cancer is the second
leading cause of death in the United States, creating a financial burden on the
healthcare system. Cancer research in the past decade has suggested that new

1

Weisse, Allen B. (1991). Medical Odysseys: The Different and Sometimes Unexpected Pathways to
Twentieth-Century Medical Discoveries. Rutgers University Press. p. 127.
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treatment methods, other than chemotherapy, radiation, or surgery, are necessary
to dramatically improve cancer patient outcomes.
The cancer stem cell hypothesis has dramatic therapeutic implications that
have the potential to mitigate the failures of chemotherapy, radiation, and surgery.
Formulated in the mid-1990s, the hypothesis postulates that cancer arises from a
small population of tumorigenic cells. These cells, called cancer stem cells (CSCs)
share many characteristics with normal stem cells found in every body tissue, such
as the abilities to self-renew and differentiate into specific types of cells. Like normal
differentiated and stem cells, CSCs divide infrequently, distinguishing them from
differentiated tumor cells.
As chemotherapeutic agents target rapidly dividing cells, CSCs are often
resistant to common cancer treatments, similar to normal differentiated and stem
cells. While chemotherapy and surgery are able to remove or kill bulk tumor cells,
they are not effective in destroying CSCs. For this reason, it is common for cancer
patients to experience relapse or metastasis. The small numbers of CSCs that persist
after traditional cancer treatments often have the ability to repopulate, sometimes
at the site of the primary tumor and other times at a distant location. Because CSCs
are such a small fraction of a tumor’s total cells, they go undetected on routine
cancer scans when they are by themselves, such as following chemotherapy,
radiation, or surgery. For this reason, it is common in the clinical setting for patients
to be in remission, then experience relapse years later.
It has become apparent in the recent years that cancer treatment must target
cancer stem cells in order to prevent cancer relapse, drug resistance, and drug
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toxicity. The objective of this research is to evaluate the question: how does the
cancer stem cell hypothesis show promise in reducing the global cancer burden?
This paper will describe the reasons for failures of traditional cancer treatments,
elucidate the need for cancer treatments that target CSCs, evaluate the effectiveness
of CSC therapies that have been studied in clinical trials, and assess the global health
implications of basing future cancer therapies on the cancer stem cell hypothesis. It
will take both a scientific and global health perspective, illustrating the intersections
between both fields of study.

Literature Review
Cancer is one of the major global health issues, affecting millions annually
across the globe. There are currently thousands of academic sources on different
approaches that must be taken to combat the cancer crisis. Some sources describe
how prevention must be improved and made more widespread; others focus on
biological processes of cancer and how treatments must be modified. Sources
collected for this research focus on the latter issue, and most reach the consensus
that the cancer stem cell hypothesis has major therapeutic implications. This
research is based mainly on primary research reports and somewhat on literature
reviews from scientific journals.
Primary and secondary information from medical journals on the cancer
stem cell hypothesis indicate that chemotherapy, radiation, and surgery, while
reducing the bulk of tumor cells, present several problems in terms of long-term
patient survival. Reviews of literature and meta-analytical studies indicate that
chemotherapy often has unintended side effects, including toxicity. According to
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both research reports and literature reviews, the cancer stem cell hypothesis has
much potential in reducing the global cancer burden by being implicated in cancer
treatments. Drugs that target CSCs mitigate many of the problems not accounted for
or caused by chemotherapy, radiation, and surgery.
Primary reports from clinical trials of drugs that target CSCs indicate that in
many cases, patient survival is improved when they are utilized alongside
traditional cancer treatments. Research in laboratories has revealed that cancer
stem cells are drug-resistant and have potential to cause relapse in patients who
have undergone chemotherapy or surgery.
This study evaluates the implications of shifting cancer treatments away
from traditional practices to utilizing cancer stem cell targeted drugs. It emphasizes
the importance of treatments that destroy cancer stem cells, preventing the host of
problems that arise when they are not eliminated. While clinical trials evaluate the
effectiveness of single drugs, this research reviews literature and evaluates the
effectiveness of different drugs that have been trialed.

Methodology
The majority of this research is a review of current literature. Most sources
were found through PubMed, the major database for searches related to the
biological sciences and medicine. From PubMed, primary scientific journal articles
and secondary literature reviews were acquired. Several types of research papers
were collected, including studies on how the current cancer treatments are
ineffective and how the cancer stem cell hypothesis has therapeutic implications.
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Interviews were also conducted with biologists and biochemists who
specialize in cancer stem cell research. Four formal personal interviews were done
with cancer biologists from various institutions. The individuals that were
personally interviewed include Dr. Joerg Huelsken, Dr. Freddy Radtke, Dr. Cathrin
Brisken, and Dr. Daniel Constam, all of whom conduct research at École
Polytechnique Fédérale de Lausanne. One phone interview was conducted with
Patrick Gaines, Executive Director of the Gates Center for Regenerative Medicine
and Stem Cell Biology.
This methodological approach was utilized in order to gain a broad
perspective on the cancer stem cell hypothesis, from research data, reviews of
current literature, and dialogues with experts in the field. However, for this topic,
choices in the Canton of Vaud, Switzerland were limited; thus in-person interviews
were conducted only with experts from EPFL. However, each interviewee had a
unique perspective on CSC research, providing a wide variety of expertise.
When evaluating the human subjects criteria, there were no ethical issues
that arose. All interviewees gave full informed consent for the information disclosed
in interviews to be utilized in this paper. Human subjects were not part of
vulnerable populations. All sources, both primary and secondary, have been
properly and consistently cited throughout this paper.

Results
1. Failures of traditional cancer treatments
Chemotherapy is the oldest, most well known and widespread cancer
treatment utilized in medical practice. Radiation and surgery follow closely behind;
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sometimes, two or three of the aforementioned treatments are used in combination.
Chemotherapy drugs continue to be researched in clinical trials, as do radiation
procedures and combination therapies. While much progress in improving overall
cancer survival rates has been made, especially as a result of increased prescription
of combination therapies, cancer patients often experience relapse, metastasis, or
drug toxicity.
Most studies indicate that combination therapies are more effective in
improving survival rates of certain types of cancer than single-drug treatments,
though these results have not been replicated in all studies. Research conducted on
combination therapy for head and neck cancer concluded that some chemotherapy
combinations with radiotherapy more effectively treat patients with advanced stage
head and neck cancer than radiation by itself.2 Similarly, a study on outcomes and
toxicity of radiotherapy combined with chemotherapy showed improvements in
cancer survival, but a higher risk for toxicity.3 Other studies have demonstrated
increases in survival rates of combination therapy for advanced breast and lung
cancers.45 However, in a study of treatments for advanced non-small-cell lung
cancer, it was found that certain chemotherapy drugs offered no significant

2

Bonner, J.A., Harari, P.M., Giralt, J. Azarnia, N. Shin, D.M. (2006). Radiotherapy plus cetuximab for
squamous for squamous cell carcinoma of the head and neck. New EngIand Journal of Medicine, pp.
567–578
3 Beijer, Y.J. Koopman, M., Terhaard, C.H.J., Braunius, W.W., van Es, R.J.J., de Graeff, A. (2013)
Outcome and toxicity of radiotherapy combined with chemotherapy or cetuximab for head and neck
cancer: our experience in one hundred and twenty-five patients. Clinical Otolaryngology, 38(1), 6974. doi: 10.1111
4 Romond, E.H., Perez, E.A., Bryant, J., Suman, V.J., Geyer, C.E., Davidson, N.E., et al. (2005).
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England
Journal of Medicine. 353(16), 1673-84
5 Arriagada, R., Bergman, B., Dunant, A., Pignon, J.P., Vansteenkiste J. (2004). Cisplatin-based adjuvant
chemotherapy in patients with completely resected non-small-cell lung cancer. New England Journal
of Medicine, 350(4): 351-60
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advantage over other treatments in clinical trials.6 From these studies, it can be
concluded that in many cases, combination therapies offer significant advantages
over chemotherapy alone. However, combination therapy has not been
demonstrated to be effective against all types of cancer, and the severe toxicity of
combined therapies makes it crucial that innovative treatment options be explored.7
In addition, cancer tends to relapse and metastasize in later rounds of therapy, as it
develops resistance to previous drugs. This section will examine the reason for the
common failures of traditional cancer therapies using the cancer stem cell
hypothesis as a framework for analysis. The problems of drug resistance, relapse,
and toxicity will the focus of this section.
1a. Chemotherapy fails to eliminate all cancer cells, leading to drug resistance
Cancer stem cells, in recent years, have been implicated in cancer drug
resistance. Currently, there is a low efficacy of chemotherapy, radiation, and surgical
treatments on eradication of CSCs8 Tumor drug resistance appears to be related to
many characteristics of CSCs, both intrinsic and acquired.9 For example, for many
types of cancer, ionizing radiation is widely considered the best non-invasive
therapy. However, in many cases, cancer stem cells are resistant, causing this

6

Schiller, J.H., Harrington, D., Belani, C.P., Langer, C.A., Sandler, Krook, J., Zhu J, Johnson D.H. (2002)
Comparison of four chemotherary regiments for advanced non-small-cell lung cancer. New EngIand
Journal of Medicine, 346 (2002), pp. 92–98
7 Morrison R., Schleicher S.M., Sun Y., Niermann K.J., Kim S., Spratt D.E., Chung C.H., Lu B. (2011).
Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell
hypothesis. Journal of Oncology, 2011: 941876. doi: 10.1155/2011/941876
8 Koch, U., Krause, M., Baumann, M. (2010). Cancer stem cells at the crossroads of current cancer
therapy failures—radiation oncology perspective. Seminars in Cancer Biology, 20 (2), pp. 116–124
9 S. Vinogradov, X Wei. Cancer stem cells and drug resistance: the potential of nanomedicine .
Nanomedicine (Lond) 7(4) 2013 597-618
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method to fail.10 CSCs utilize several biological mechanisms that contribute to their
therapeutic resistance, described below.
First, cancer stem cells have a high level of relative dormancy and slow cell
cycle kinetics; they are usually in a quiescent state.11 Their low multiplication rate is
a hallmark of normal somatic cells, with the exception of gut epithelial stem cells.12
A generally accepted hypothesis is that CSC quiescence is a protection mechanism
against cytotoxic therapy. Chemotherapy functions to stop tumor growth by
inhibiting DNA replication or cell division of rapidly dividing cancer cells; thus, it
fails to target CSCs.
Second, cancer stem cells have a high resistance to DNA damage and a high
capacity for DNA repair.13 Noncancerous stem cells have well-developed defense
systems against mutation into carcinogenic CSCs; however, when rare genetic
alterations do occur, these defense systems serve as barriers against chemotherapy
and radiation that target cancerous DNA. In a study of cancer cell resistance against
radiation, CSCs were able to repair DNA damage done by radiation much more
quickly that all other types of cancer cells. 14 In addition, CSCs have downregulated
telomerase function, conferring cellular immortality.15 Telomerase an enzyme that

10

Morrison, et al., 2011
Han, L., Shi, S., Gong, T., Zhang, Z., & Sun, X. (2013). Cancer stem cells: Therapeutic implications and
perspectives in cancer therapy. Acta Pharmaceutica Sinica B, 3(2), 65-75. Retrieved October 20, 2014,
from http://www.sciencedirect.com/science/article/pii/S2211383513000208
12 Borst, P. (2012). Cancer drug pan-resistance: Pumps, cancer stem cells, quiescence, epithelial to
mesenchymal transition, blocked cell death pathways, persisters or what? Open Biology, 2(5).
Retrieved October 28, 2014, from NCBI.
13 Morrison, et al., 2011
14 Eyler, C. E. and Rich, J. N. (2008). Survival of the fittest: cancer stem cells in therapeutic resistance
and angiogenesis, Journal of Clinical Oncology, 26(17), pp. 2839–2845.
15 Morrison, et al., 2011
11
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maintains repeated DNA sequences (telomeres) at the ends of chromosomal
strands, which promote cell survival.16
Third, CSCs of several different cancer types have displayed a high
expression of multiple drug resistant membrane transporters, namely ABC
transporters.17 These cell surface pumps function to preserve the genomes of
normal stem cells against chemical mutagens, thereby precluding carcinogenesis.
CSCs derive resistance to chemical mutagens, such as chemotherapy, from
preexisting drug efflux pumps in normal stem cells from which CSCs originated,
similar to DNA damage resistance.18
Fourth, cancer stem cells have a high resistance to apoptosis. Several
mechanisms of CSC resistance to apoptosis have been identified, including the
amplification of apoptosis inhibitor proteins. In a study of hepatocellular carcinoma
CSCs, it was found that CSCs preferentially activate certain cell survival pathways.19
Furthermore, CSCs have been shown to be resistant to the mitochondrial pathway of
apoptosis20 as well as a specific nuclear factor that is downregulated in CSCs.21
Fifth, the microenvironment of CSCs contributes to their resistance of
common cancer therapies. Oxygen sensitizes cells to radiation due to its ability to

16

Dikmen, Z. G., Gellert, G. C., Jackson, S., et al. (2005) In vivo inhibition of lung cancer by GRN163L: a
novel human telomerase inhibitor. Cancer Research, 65(17), pp. 7866–7873.
17 Dean, M. (2009). ABC transporters, drug resistance, and cancer stem cells. Journal of Mammary
Gland Biology and Neoplasia, 14(1), pp. 3–9.
18 Dean, 2009
19 Ma, S., Lee, T. K., Zheng, B.J., Chan, K.W., Guan, X.Y. (2008). CD133+ HCC cancer stem cells confer
chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene, 27(12), pp.
1749–1758.
20 Vellanki, S.H.K., Grabrucker, A., Liebau, S., et al. (2009) Small-molecule XIAP inhibitors enhance γirradiation-induced apoptosis in glioblastoma. Neoplasia, 11(8). pp. 743–752.
21 Sarkar, F.H., Li, Y., Wang, Z., Kong, D. (2008) NF-κB signaling pathway and its therapeutic
implications in human diseases. International Reviews of Immunology, 27(5) pp. 293–319.
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make DNA more vulnerable to damage.22 Since radiotherapy is dependent on
oxygen-free radicals, areas of low oxygen levels within tumors produce
microenvironments that are conducive to radiation-induced destruction.23 However,
one study unexpectedly concluded that CSCs commonly reside near vascular areas.24
Thus, antiangiogenic chemotherapy may increase CSC drug resistance to
radiotherapy by decreasing oxygen availability.
Sixth, CSC heterogeneity contributes to their drug resistance. During therapy,
treatment resistant cells within a heterogeneous tumor population can be
preferentially selected for, resulting in a more aggressive and malignant outcome.
Pharmacological eradication of entire tumors is made difficult by CSC heterogeneity,
because they exhibit variable expression of drug-targeted genetic markers.25 CSCs
that have drug resistant properties flourish, later creating more drug-resistant
tumors.
Several studies have validated the drug resistant properties of CSCs,
indicating that alternate therapies and drug delivery methods are necessary to
continue improving cancer patient outcomes. Continuing to utilize chemotherapy
without therapies that target CSCs is inefficient from a public health perspective, as
drug resistant cancer cells often metastasize or cause relapse. The importance of
utilizing cancer therapies that target CSCs to combat drug resistance is discussed
later.

22

Diehn, M., Cho, R.W., Lobo, N.A., et al. (2009) Association of reactive oxygen species levels and
radioresistance in cancer stem cells. Nature, 458(7239), pp. 780–783.
23 Diehn, et al., 2009
24 Calabrese, C., Poppleton, H., Kocak, M., et al. (2007) A perivascular niche for brain tumor stem cells,
Cancer Cell, 11(1) pp. 69–82.
25 Morrison, et al., 2011
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1b. Relapse

Cancer relapse is a common issue that affects a large percentage of cancer
survivors. It begins with cancer cells that the first treatment didn’t fully remove or
destroy; there is growing evidence that these cells are usually drug-resistant CSCs.
Furthermore, since CSCs are the only cancer cells that are tumorigenic, they are the
only tumor cells that have potential to recolonize, either in the location of the
primary tumor or at a distance. Thus, tumor recurrence due to CSCs is directly
related to their drug-resistant properties. This section examines chemotherapy,
radiation, and surgery failures in terms of cancer relapse.
Cancer stem cells consist a small fraction of all tumor cells in most cancers.
Standard cancer treatment only shrinks tumors to their CSC progenitors, until the
remaining cancer stem cells are below the detectable range. 26 The most common
anti-cancer agents consist of paclitaxel, doxorubicin, and cisplatin. While they are
capable of high cytotoxicity that kills the bulk of the tumor, they are non-targeting
and often result in tumor relapse due to drug resistance. 27 For example, small lung
cancer has been clinically characterized by early recurrence after complete
response to combination chemotherapy initially.28 One study conducted on this type
of cancer found that after the initial cycles of treatment, CSCs persisted, frequently
forming a chemoresistant tumor later.29

26

Han, et al., 2013
Rich, J.N, Bao, S. (2007). Chemotherapy and cancer stem cells. Cell Stem Cell, 1(4), pp. 353–355.
28 Hamilton G, Olszewski U (2013) Chemotherapy-induced Enrichment of Cancer Stem Cells in Lung
Cancer. Journal of Bioanalysis and Biomedicine, S9(003), n.p. doi: 10.4172/1948-593X.S9-003
29 Hamilton, et al., 2013
27
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In a study of ovarian cancer, it was found that CSCs commonly lead to relapse
from drug resistance after the initial rounds of treatment.30 Ovarian cancer has been
found to partially consist of heterogeneous CSCs, leading to drug resistance, thereby
resulting in recurrence. Similar to small cell lung cancer, a regimen of chemotherapy
following cytroreuctive surgery is initially effective. However, within a few months
of this initial treatment, platinum-resistance of cancer stem cells leads to tumor
relapse.31 The secondary tumors are more drug resistant and malignant due to the
selection for critical drug-resistant CSCs.
Growing evidence also suggests that chemotherapy may increase chances of
acute myeloid leukemia relapse. Ley et al. found that while initial treatment with
chemotherapy usually puts cancer into remission for 2-3 years, about 80 percent of
AML patients die within five years of their diagnosis after chemotherapy fails to
keep their cancer in remission and they experience relapse.32 In all cases of relapse,
chemotherapy failed to eradicate the “founding clone,” or cancer stem cells. These
findings indicate that eradicating CSCs and entire populations of their “subclones” is
the key to achieving a cure for the disease.
Chemotherapy drug resistance of CSCs evidently leads to tumor relapse in
many types of cancer. Chemotherapy drugs fail to eliminate tumorigenic CSCs,

30

Kakar, S., Ratajczak, M., Powell, K., Moghadamfalahi, M., Miller, D., Batra, S., & Singh, S. (2014).
Withaferin A Alone and in Combination with Cisplatin Suppresses Growth and Metastasis of Ovarian
Cancer by Targeting Putative Cancer Stem Cells. Plos One, 9(9). Retrieved October 10, 2014, from
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0107596
31 Kakar, et al., 2014
32 Ley, T., DiPersio, J., & Wilson, R. (n.d.). Chemotherapy May Influence Leukemia Relapse. The
Genome Institute. Retrieved October 2, 2014, from
http://genome.wustl.edu/articles/detail/chemotherapy-may-influence-leukemia-relapse/
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causing a more malignant tumor to grow following initial treatments. 33 As
chemotherapy preferentially selects for the most drug-resistant CSCs which are
progenitors to more malignant bulk tumor cells, it is important that therapies
targeting CSCs are utilized in conjunction with chemotherapy.
1c. Toxicity
Chemotherapy poses problems in addition to drug resistance and relapse,
namely toxicity. Patients who undergo combination therapy are particularly at risk.
However, combination therapy is frequently more effective than single
chemotherapy drugs or radiation alone. Thus, it is often the treatment of choice,
despite its unwanted side effects.
A retrospective analysis of combination radiotherapy and chemotherapy in
patients with lung cancer associated high levels of toxicity with combined therapy.
Compared to radiotherapy alone, simultaneous radiotherapy and cetuximab
chemotherapy increase survival rates for locally advanced health and neck
squamous cell carcinoma patients. However, of the 125 patients receiving
treatment, five died due to heart failure from toxicity. Furthermore, dermatological
toxicity prevented several patients from completing treatment and 59 percent of
patients from receiving the full dose of cetuximab, leading to less successful
outcomes from treatment. However, it was concluded that radiotherapy combined
with cetuximab is justified by an increased two-year survival rate, despite an
increased risk of toxicity.34

33
34

Constam, Daniel. Personal Interview. 12 Nov 2014.
Beijer, et al, 2013
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In addition to toxicity leading to cardiovascular failure, Bressler (1997)
observed that neurotoxicity from chemotherapy has been commonly reported in
patients taking antineoplastic drugs.35 According to Bressler, there are frequently no
treatments

for these

toxicities; thus,

oncologists decide

to discontinue

chemotherapy treatment based on a number of criteria, including severity of
symptoms and response to therapy. Among drugs that have caused neurotoxicity is
5-Fluoraouracil, which has led to cerebellar toxicity, ataxia of the trunk or
extremities, and dizziness. Cerebellar toxicity appears to have an increased
incidence with higher doses of the drug; though it has been observed at lower doses
as well. Within weeks of stopping therapy, the syndrome is reversible; thus,
physicians commonly decide to discontinue treatment to prevent further toxic
effects.36
In a clinical trial of the efficacy of combined fluorouracil, cisplatin, and
radiation therapy for treatment of localized carcinoma of the esophagus, Herskovic
(1992) et al found that the combined therapy was much more effective than
radiation alone, but with the cost of severe side effects. Compared with the control
group who received radiation therapy alone, the experimental group receiving
concurrent therapy with fluorouracil, cisplatin and radiation experienced increased
toxic side effects. In the combined-therapy group, one patient died from renal and
bone marrow failure. In 44 percent of patients receiving combined therapy, side
effects were severe; in 20 percent they were life threatening, compared to 25

35

Bressler, L. (1997). Neurotoxicity from Chemotherapy. PMPR Rharmacotherapeutics, 1(652). n.p.
Retrieved November 2, 2014.
36 Bressler, et al, 1997
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percent and 3 percent, respectively, for those receiving only radiation. Despite the
side effects, a significant survival advantage was observed for patients receiving
combined chemotherapy and radiation as compared with radiation alone. 37
It is clear that combined therapy is more successful than single
chemotherapy drugs alone for treating many types of cancer; yet the toxicity of
these combined therapies cannot be overlooked. To further improve survival rates
of cancer patients, treatments other than combined chemotherapy and radiation
must be utilized in order to eliminate these toxic side effects. Targeting CSCs
reduces the need for combination radiotherapy and chemotherapy, or higher doses
of chemotherapy. The destruction of CSCs with CSC-specific cancer drugs precludes
relapse, because differentiated tumor cells cannot proliferate on their own.

2. The CSC hypothesis from a global health perspective
The cancer stem cell hypothesis is a key example of how cellular biology
influences treatments at the population level, thus impacting public and global
health. Theoretically, more effective cancer treatments than chemotherapy,
radiation, and surgery, lead to lower rates of drug resistance, thus preventing cancer
relapse and metastasis. Both of these complications place a burden on healthcare
systems and their constituents, while pharmaceutical industries profit. Thus, the
need for more effective and less toxic cancer therapies is evident, and the CSC
hypothesis shows promise according to myriad experts around the globe.
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2a. The financial burdens of cancer

Cancer has a large financial impact on individuals and healthcare systems
around the globe. According to a study of costs incurred by insured breast cancer
patients, in 2004, cancer accounted for an average of 98 percent, 41 percent, and 26
percent of monthly income among breast cancer patients with income levels of
<30,000, 30,000-60,000, and >60,000 US dollars, respectively.38 In the same study, it
was found that women lost a monthly average of 727 dollars after their breast
cancer diagnosis.39 Repeated chemotherapy treatments add to this burden; thus,
metastasis increases the average percentage. According to Dr. Freddy Radke,
developing drugs that successfully destroy CSCs reduces the risks of metastasis and
relapse to near zero. As a result, CSC-targeted therapy hypothetically eliminates
subsequent rounds of treatment, reducing the financial burden on families.
On a larger scale, the economy takes a hit from high costs of cancer.
Currently, the NIH estimates that over 200 billion dollars is spent on cancer
annually in the United States; this number continues to increase and is mainly due
to indirect mortality costs.40 Cancer mortality occurs when CSCs spread to distant
locations, causing relapse and metastasis. Thus, eliminating this possibility with
CSC-targeted therapies will greatly reduce cancer deaths, thereby diminishing the
economic burden of cancer mortality.

38 Arozullah, A.M., Calhoun, E.A., Wolf, M., Finley, D., et al. (2004). Estimates from a study of insured
women with breast cancer. Supportive Oncology, 2(3), pp. 271-278.
39 Arozullah, et al., 2004
40 American Cancer Society. Cancer Facts & Figures 2014. Atlanta, Ga. 2014.
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2b. The psychosocial burden of cancer and chemotherapy

According to Cancer Care for the Whole Patient: Meeting Psychsocial Health
Needs, people with cancer currently face risks such as physical impairment,
disability, and inability to take part in daily activities, partially due to harsh
treatment side effects. Many cancer patients have chronic cancer that requires
intermittent or continuous treatment regimens, similar to heart disease. Cancer, in
recent years, has increasingly met the definition of chronic; its permanence and
resulting residual disability are caused by irreversible physiological changes, and its
patients require continuous care. As a result of cancer’s continuousness, patients
and their loved ones must cope emotionally with the stresses created by the
debilitating and often life-threatening treatments, and pain and fatigue even after
they are declared in remission. Thus, psychological states categorized as depression
are common in cancer patients, and fear of relapse is characteristic of those in
remission.
As depression and stress in cancer patients are largely a result of the
treatments

they

must

undergo,

shifting

common

therapies

away

from

chemotherapy and radiation and towards targeted, CSC-specific drugs will prove
effective in reducing the psychosocial burden of cancer. Diminishing the risk of
relapse and metastasis with targeted drugs will also lessen fear and depressive
feelings in patients. Furthermore, the milder to nonexistent side effects associated
with CSC-targeted therapies will lessen the physical, therefore psychological, burden
on cancer patients.
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3. Necessary for cancer treatments to target CSCs to prevent relapse
While combined therapies have proven more effective in improving five and
ten-year survival rates for most types of cancer, it has become clear in recent years
that drug resistance of cancer stem cells to these treatments will continue to lead to
relapse in certain patients. Thus, it is necessary for cancer stem cells to be
eliminated in addition to bulk tumor cells; it is essential that novel treatments be
utilized. According to much cancer research today, it is impossible to achieve a cure
for cancer without eliminating all CSCs.41 Currently, the most challenging barrier in
cancer therapy lies in establishing a precise way to target and eliminate CSCs.42
While this theory can be generalized across most types of cancer, certain studies
suggest that the cancer stem cell theory may not explain initiation of all cancer
types. For example, researchers have not yet isolated CSCs from B-cell precursor
ALL.43 Despite this example, the necessity for treatments to target CSCs has become
evident. This section examines the potential implications of CSC-targeting therapies
in terms of preventing drug resistance, relapse, and toxicity.
As CSCs are accepted as a chief source of cancer relapse after conventional
therapy, failure to completely eliminate them with these therapies can lead to
recurrence.44 They constitute a discrete subpopulation of tumors, usually making up
only five to 20 percent of all tumor cells.45 However, they are the only tumor cells

41 Chen, L.S., Wang, A.X., Dong, B., Pu, K.F., Yuan, L.H., Zhu, Y.M. (2012). A new prospect in cancer
therapy: targeting cancer stem cells to eradicate cancer. Chinese Journal of Cancer, 31(12), pp. 564–
572.
42 Chen, et al., 2012
43 Bomken S, Fišer K, Heidenreich O, et al. (2010) Understanding the cancer stem cell. British Journal
of Cancer, 103(4), pp. 439–445.
44 Chen, et al., 2012
45 Yu, et al., 2012

The End of an Era

Paton 23

that are tumorigenic, indicating that they are the most important cancer cells to
eliminate during therapy. They also have been found to promote angiogenesis
during tumor development in certain types of cancer,46 demonstrating that they
lead to tumor cell proliferation in ways other that tumorigenicity. Several properties
of CSCs are related to cancer relapse, indicating a need for CSC-targeted therapies.
Chiefly, the tumorigenic properties of CSCs contribute to cancer relapse
months or years after the primary tumor was thought to have been eliminated.
Similar to normal stem cells, CSCs are progenitors to differentiated tumor cells. CSCs
maintain the ability to sustain the bulk tumor or, after undergoing specific genetic
changes, give rise to new tumors in distant locations. CSCs are the only tumor cells
that are able to support tumors and give rise to new, distinct tumors; thus, without
them, tumor growth, metastasis, and relapse are impossible. The unique
tumorigenic ability of CSCs makes them the ideal target for cancer drugs.
According to Yu et al (2012), in addition to tumorigenicity, cancer stem cells
maintain the ability to self-renew. This characteristic, similar to tumorigenicity, was
derived from normal, healthy stem cells. Asymmetric replication perpetuates stem
cells in their undifferentiated state; during which one of the daughter cells remains
an undifferentiated CSC while the other is genetically programmed for
specialization. However, stem cells also retain the ability to divide symmetrically
under stress to rapidly increase their population, resulting in two CSC daughter cells
rather than two distinct cell types. These processes evolved to ensure both the

46 Bao S.D., Wu Q.L., Sathornsumetee S., et al. (2006). Stem cell-like glioma cells promote tumor
angiogenesis through vascular endothelial growth factor. Cancer Research, 66(16), pp. 7843–7848.
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stability and versatility of a healthy, normal stem cell population.47 Cancer stem cells
derive both methods of division from normal stem cells, circumventing the latter
mechanism that gives normal stem cells the ability to rapidly replicate.48 This
quality allows CSCs to quickly repopulate after chemotherapy, radiation, or surgery.
Differentiated tumor cells do not maintain the ability to self-renew, indicating that
targeting CSCs in cancer therapies has significantly more potential to reduce the risk
of relapse.
An additional characteristic that contributes to the resilience of CSCs is their
migratory ability. CSCs coopt the ability of normal stem cells to migrate to locations
distant from the primary tumor, invade organs in these distant locations, and
colonize by undergoing asymmetrical replication.49 These metastatic colonies are
largely responsible for tumor recurrence, and are often undetectable for months or
years after initial therapies. Furthermore, metastatic tumor cells have several drug
resistant properties not shared by primary tumor cells, making the prognosis for
patients with relapse or metastasis highly unfavorable. Therapies that target CSC
greatly reduce the risk for cancer relapse and metastasis, thereby eliminating a need
for additional, toxic drug treatments following initial therapies.
Relapse remains a widespread fear among cancer survivors, and can be
prevented with CSC-targeting therapies. Because of the biological differences that
exist between CSCs and non-CSCs, similar to those between normal stem cells and
differentiated cells, CSCs are the only cancer cells that maintain the ability to cause
47
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recurrences. 50 Therapies that destroy differentiated cancer cells preferentially
select for CSCs, increasing their drug resistant properties and resilience,51 and kill
differentiated cancer cells that lack potential to sustain cancer growth.52 Thus,
developing novel treatment strategies that are effective against CSCs53 has become a
top priority for many researchers in the pharmaceutical industry.

4. Barriers to overcoming CSC drug resistance with treatments that
target CSCs
CSCs derive many of their characteristics from normal stem cells. They also
appear to share more characteristics with healthy differentiated cells than
differentiated tumor cells. Shared properties of CSCs and normal cells present a
barrier for CSC-targeted treatment development, as many therapies that have the
potential to destroy CSCs could also harm healthy cells.54 However, it is imperative
that signatures unique to CSCs be identified to develop CSC-specific treatments.
Overcoming the problem of drug resistance precludes the ability of tumor cells to
metastasize or relapse. Furthermore, first-round treatment cannot be repeated due
to drug resistance of CSCs, making the prognosis less favorable as treatment options
run out. However, targeting CSCs mitigates this problem, and thus, it is crucial that
the several treatment resistance mechanisms discussed in the previous section on
drug resistance of CSCs are overcome.
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The first of these mechanisms is the lower proliferation rate, or quiescence,
of CSCs

55

than differentiated tumor cells. As tumors are histologically

heterogeneous, different molecular features within a single tumor exhibit varying
responses to cancer therapeutics.56 Chemotherapy drugs target rapidly dividing
tumor cells, while slowly proliferating cells, such as CSCs, escape.57 Thus, the most
drug resistant cells within a tumor, namely CSCs, proliferate, resulting in increased
malignancy of cancer cells. Thus, it is important for novel therapies to target CSCs in
order to eliminate the chance of relapse from drug resistance due to CSC quiescence.
Several ways of overcoming this treatment barrier have been proposed, including
blocking certain cell signaling pathways that cause cells to proliferate at a normal
rate.58
Another treatment resistance characteristic of CSCs is their presentation of
surface proteins that have the ability to efflux drugs across the plasma membrane.59
These proteins are known as ATP-binding cassette transporters, and inhibiting them
makes CSCs more sensitive to anti-cancer drugs. However, not all CSCs express
these proteins. One study on tumorigenicity of different types of CSCs found that
CSCs that expressed these transporters were more tumorigenic than ones that did
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not, though the CSCs without them were still tumorigenic but to a lesser degree.60
Furthermore, the expression of ATP-binding cassette transporters is not limited to
CSCs; normal kidney cells present high levels on their plasma membranes.61 This
similarity presents an additional problem for overcoming CSC drug resistance.
Finally, certain cell signaling pathways and transcription factors contribute
to CSC therapy-resistance.62 Among these is Wnt signaling, a group of signal
transduction pathways that are important for cell proliferation and migration. They
have been implicated in remaining cancer cells after radiation therapy63 and are
overexpressed in certain cancers. For example, Wnt is necessary for the radiationresistance of mammary epithelial CSCs from mice. 64 Furthermore, early lung
metastases overexpresses components of the Wnt signaling pathway, while the
downregulation of these components inhibits metastasis. 65 However, signaling
processes such as Wnt are necessary for certain healthy cell processes; thus,
treatments inhibiting Wnt signaling must be delivered to the specific tumor site.
Clearly, cancer stem cells share many characteristics with healthy cells that
make targeting them with drugs particularly difficult. However, as drug resistance
results chiefly from these properties of CSCs, it is important that certain signatures
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of CSCs be targeted by novel therapies. Alternatively, drugs have been developed to
chemically alter CSCs to make certain properties more similar to differentiated
cancer cells. Thus, chemotherapy or other drugs targeting bulk tumor cells in
combination with CSC-targeted drugs offers a promising solution to the problem of
CSC drug resistance.

5. Potential therapies that target CSCs
Recent evidence has made the dire need for CSC-targeting therapies
apparent. Cancer cannot be cured without eliminating CSCs in addition to bulk
tumor cells; without CSCs, tumorigenesis becomes impossible.66 While the problem
of drug resistance has been somewhat mitigated by use of combination
chemotherapy and radiation, the toxic effects of these combined therapies
frequently make their outcomes unfavorable. Despite the success of combined
therapies in improving cancer survival rates, for some types of cancer, these
therapies are far from 100 percent effective. The cancer stem cell hypothesis
presents the scientific community with a promising approach to finally discovering
a cure for cancer, and several drugs that target CSCs have already undergone clinical
trials.
Several facets of CSC-targeting therapies must be addressed in drug
development,67 including signatures of CSCs to be targeted and drug delivery
methods. Certain cell signaling pathways that are implicated in cancer can be
targeted in CSCs. However, these processes must either be specific to CSCs or drugs
must be delivered to the exact location to the tumor, otherwise the risk of toxicity or
66
67
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healthy cell damage exists. Thus, both the cellular mechanisms and delivery of drugs
are of equal importance. This section examines bench research and clinical trials of
CSC-targeting drugs, considering therapies that sensitize CSCs to conventional
cancer drugs, drugs that inhibit certain CSC signaling pathways, and nanoparticle
drug delivery.
5a. Drugs that target stem cell markers
Certain signatures of cancer stem cells play a vital role in their functioning,
and thus make them logical targets for therapy. Often, cancer stem cells have higher
expression of certain proteins or cell signaling pathways than bulk tumor cells,
making them identifiable within a tumor. These markers include ABC transporters,
cell-cell matrix receptors, and several cell signaling receptors.
Considering the similarities between normal, healthy stem cells and cancer
stem cells is crucial for CSC-targeting drug development. This idea is particularly
important for chemists creating drugs that target ABC transporters. Normal stem
cells have a relatively high gene expression of drug efflux transporters from the ABC
gene family, 68 allowing them to efflux drugs and toxins across their plasma
membranes. While they allow healthy stem cells to effectively preserve their
genomes against chemical mutagens that can lead to carcinogenesis, CSCs have
coopted this resistance to DNA damage. Instead of protecting a healthy genome,
however, they use the preexisting DNA repair systems of normal stem cells to
prevent their DNA repair, thus preserving a genome that is conducive to

68
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carcinogenesis.69 The high CSC expression of these transporters has been used to
identify CSCs within a tumor, making them obvious drug targets within a cluster of
cancer cells.70 Drugs that block the function of efflux transporters or down-regulate
their expression potentially have the ability to circumvent CSC chemoresistance
mechanisms.71
5b. Drugs that target CSC signaling pathways
Signal transduction pathways that have well-established roles in the
development and progression of tumors have recently found to be critical for CSC
generation, differentiation, and drug resistance. Among these signaling pathways
are Notch1 and Notch4, which have been implicated in breast cancer and leukemia;
Wnt signaling, which is implicated in nearly every cancer type; and the hedgehog
signaling pathways, which also is implicated in a broad range of cancers.
Notch: The Notch1 and Notch4 signaling pathways have been implicated in
breast cancer and acute lymphoblastic leukemia; their unique levels of expression
has aided chemists in the identification and isolation of breast CSCs.72 Isolated CSCs
from breast cancer are enriched for Notch4 and deficient in Notch1,73 which
presents potential therapeutic targets. Experimentally, inhibiting the Notch4
signaling pathway has prevented tumor formation.74
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Real et al’s (2009) in vitro study of drugs that inhibit Notch1 signaling with
gamma-secreatase inhibitors (GSIs) for treatment of t-cell acute lymphoblastic
leukemia (T-ALL) demonstrates the effectiveness of anti-Notch1 therapies against
T-ALL. T-ALL, while having a higher cure rate than the past with improved
chemotherapy drugs, is highly associated with chemotherapy resistance and
relapse. The chemotherapy drugs glucocorticoids play an integral role in lymphoid
tumor treatment with their ability to induce apoptosis in lymphoid stem cells.
However, patients with ALL in relapse have increased resistance to therapy with
glucocorticoids. This resistance is chiefly due to immature T-cell resistance to
glucocorticoid-induced cell death as a result of constitutive activation of Notch1
signaling. This clinical trial tested the effectiveness of GSIs in sensitizing the Notch1
pathway in ALL CSCs to glucocorticoids. It was found that inhibition of the Notch1
pathway by GSIs triggers a more robust response to glucocorticoid-induced
apoptosis in T-ALL cells that would be otherwise resistant. However, while GSIs are
effective inhibitors of the Notch1 pathway in cancer stem cells, making them
effective anti-CSC agents, they often result in the inhibition of Notch signaling in the
intestinal tract, leading to gastrointestinal toxicity. In the study, it was found that cotreatment with glucocorticoids inhibited this GSI-induced toxicity.75 This issue also
illustrates the importance of a drug delivery system that allows for specific targeting
of cancer stem cells.
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Wnt/β-catenin pathway: The Wnt/β-catenin pathway has been implicated in
the initiation and progression of many types of leukemia,76 gliomas,77 and colon
cancer. 78 According to Dr. Joerg Huelsken, understanding the Wnt signaling
pathway, in addition to other modes of cellular signal transduction, is critical to
understanding the mechanisms of CSC tumorigenesis. Dr. Daniel Constam
articulated the importance of the Wnt pathway in CSC differentiation and
proliferation, indicating that its upregulation with mutations can lead to
tumorigenesis. Mutations in genes that control the Wnt pathway have correlated to
several types of cancers; the pathway, for example, leads to increased expression of
anti-apoptotic genes.79 This signaling pathway is critical for regulation of stem cell
survival, and has been implicated in residual cancer following radiation therapy.80
Thus, inhibition of the Wnt/β-catenin pathway shows promise in reducing the
genomic instability and drug resistance that results from its upregulation. Several
natural compounds have been found to be effective at inhibiting this signaling
pathway, including piperine and curcumin.81 Previously, both had been effectual in
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preventing a broad range of cancers.82 83 In addition, it was found that piperine
increases the bioavailability of curcumin, giving the combination additional
therapeutic efficacy.84
The Wnt/ β-catenin pathway has been seen to promote genetic instability
and tolerance to DNA damage, which is part of a positive feedback loop in CSCs as
mutations in DNA accumulate.85 This instability continues to be promoted after
radiation therapy, allowing cancer cells to develop adaptive mutations and survive
treatments. Inhibitors of the Wnt signaling pathway have been developed in
laboratories to prevent the tumorigenic ability of CSCs. Among these molecules are
monoclonal antibodies against two specific Wnt pathways.86 In a clinical trial of CSC
drugs at the University of Colorado School of Medicine Gates Center for
Regenerative Medicine and Stem Cell Biology, a patient who received a Wnt
inhibitor drug has been four years in remission from a stage 4 diagnosis with no
side effects.87
Hedgehog: According to a study by Merchanct, et al (2010), the Hedgehog
(Hh) signaling pathway has additionally been implicated in a wide variety of
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cancers.88 While early clinical trials with Hh inhibitors have validated the pathway
as an anti-cancer target, several biological mechanisms of the Hh signaling sequence
remain unclear. However, previously unexplained clinical phenomena can be
partially accounted for by Hh signal transduction in the self-renewal of CSCs and
development of metastatic disease. Additionally, inhibitors of the Hh signaling
pathway are one among the few agents that are formally examining the CSC
hypothesis in the clinical setting.89
5c. Nanoparticle drug delivery
Nanoparticle drug delivery offers significant advantages over small molecule
pharmaceuticals used in clinical practice. Among its benefits is a reduced risk of offtarget toxicities, which are common among drugs that target signaling pathways
that are utilized in both CSCs and normal cells.90 Furthermore, they address the
issue of CSC drug resistance by sequestering drug agents at a high concentration and
releasing them within CSCs following cellular uptake, overcoming their drug efflux
resistance mechanisms.91 Thus, nanoparticle drug delivery shows promise in
reducing the financial burden of drug resistance and hospital admissions due to
toxicity.
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In one study done by Lim et al, the effectiveness of a sugar-encapsulated
nanoparticle formulation for brain tumor treatment was investigated.92 Curcumin, a
natural anti-CSC agent, works by inhibiting the Wnt pathway. Its bioavailability was
greatly increased when added to the nanoparticle formulation, increasing the rates
of CSC cell cycle arrest and apoptosis.93 A >50 percent decrease in the CSC
populations were observed with this treatment, indicating that it has activity against
CSC activity of some brain tumors.94
It is clear that a systematic approach is necessary for CSC-targeted drug
delivery, taking into account the interactions of drugs with healthy cells. According
to Dr. Patrick Gaines, general drug delivery is necessary to eliminate all metastatic
sites of cancer. It is likely that a systemic but targeted approach to CSC destruction
will prove most effective; nanoparticles accomplish both. However, several other
biomedical technologies also show promise in achieving drug delivery targeted to
CSCs; thus, further research is to be done in this area.

Conclusion
The burden of cancer on individuals, their families, healthcare systems, and
the economy cannot be ignored. While chemotherapy, radiation, and surgical
procedures are continually advancing and improving cancer survival rates, relapse
and metastasis have not been addressed. The toxicity and other side effects of
traditional cancer treatments cause physiological and psychological stress on
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patients, indicating a need for less harmful, more effective cancer treatments. The
cancer stem cell hypothesis has shifted the focus of researchers from
chemotherapeutic agents to drugs that target the only tumorigenic cells in cancer:
cancer stem cells. Because chemotherapy fails to eliminate CSCs, more malignant,
drug-resistant cancer cells often proliferate in metastatic sites or relapse years later,
making patients’ prognoses unfavorable. The cancer stem cell hypothesis is now
widely accepted as a model for tumorigenicity, indicating a need for CSC-targeted
therapies. In recent years, researchers have been working to identify CSC signatures
that are targetable by drug agents. Several drugs are undergoing clinical trials, and
have shown promise in eliminating CSCs and leading to remission without relapse.
To reduce the global cancer burden, it is imperative that CSC-targeted therapies be
trialed and developed by pharmaceutical companies.
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ISP Work Journal
20 October 2014
Preliminary Research, United Nations Library in Geneva, Switzerland
• Finalized topic, began outline of paper

21 October 2014
Preliminary research, UN Library
• Emailed doctors Keith Brennan (University of Manchester), Douglas Hanahan (EPFL), Peter
ten Dijke (Leiden University Medical Center), and Patrick Gaines (University of Colorado
Gates Center)
• Began collecting journal articles on failures of chemotherapy from Santa Clara University
Databases

22 October 2014
Preliminary research, UN Library
• Received referral from Dr. Douglas Hanahan to contact Dr. Joerg Huelsken (EPFL)
• Emailed Dr. Joerg Huelsken, who researches Wnt and Notch signaling pathways in cancer
stem cells, for permission to conduct formal interview
• Continued collecting scholarly articles on chemotherapy failures, primarily through the
PubMed database

23 October 2014
Preliminary research, UN Library
• Patrick Gaines accepted interview request; formulated interview questions, schedule time
for 13 November 2014 at 20.00
• Emailed Brennan, ten Dijke, and Huelsken for the second time, with requests to interview

24 October 2014
Preliminary research, SIT Office Nyon
• Completed initial outline of paper
• Collected journal articles on potential CSC-targeting therapies

27 October 2014
Research, UN Library
• Joerg Huelsken accepted interview request, proposes interview to be in Lausanne on 3
November 2014 at 16.00
• Formulated questions for interview with Dr. Huelsken

28 October 2014
Research, UN Library
• Incorporated scholarly articles and other sources into my initial outline
• Emailed Freddy Radtke (EPFL), asking for permission for formal interview

29 October 2014
Research, UN Library
• Received permission from Freddy Radke for interview, proposes interview to take place at
EPFL on 5 November 2014 at 13.00
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Wrote introduction of paper, continue collecting scholarly articles and incorporating them
into my outline

30 October 2014
Attend the seminar Studying therapy escape mechanisms in a mouse model for BRCA1-mutated breast
cancer, conducted by Sven Rottenber, Institute of Animal Pathology, Bern, and hosted by Joerg
Huelsken
• This seminar helped me gain background information on drug resistance mechanisms of
CSCs, though some aspects of it were difficult to understand
• I had the opportunity to speak with Joerg Huelsken after the seminar about his work, which
led me to revise my interview questions for him, making them more specific to his research

31 October 2014
Writing, UN Library
• Drafted an initial literature review for paper, detailing the scientific nature of the vast
majority of my sources
• Drafted a rough methodology section of my paper

3 November 2014
Interview with Dr. Joerg Huelsken, École Polytechnique Fédérale de Lausanne, 16.00-16.20
• Gave me additional interview contacts, Dr. Daniel Constam (EPFL) and Dr. Cathrin Brisken
(EPFL)
Emailed Dr. Constam and Dr. Brisken, asking for permission to interview them and mentioning
referral from Dr. Huelsken

4 November 2014
Writing, UN Library
• Began writing the section of my paper that details potential CSC-targeting therapies,
including information from my interview with Dr. Huelsken
• Received reply from Dr. Constam, proposing interview on 12 November 2014 at 14.00 in
Lausanne

5 November 2014
Interview with Freddy Radtke, École Polytechnique Fédérale de Lausanne, 13.00-13.45
• Was asked to review section of paper where I paraphrase him to make sure information is
accurate
Writing, Lausanne
• Continued writing CSC-targeted therapies section of paper, including interview with Dr.
Radtke
• Sent this section to Dr. Radke

6 November 2014
Writing, UN Library
• Received approval from Dr. Radke to include section where I paraphrase him in my paper
• Completed draft of CSC-targeted therapies section

7 November 2014
Writing, UN Library
• Began writing the section of my paper on failures of chemotherapy
• Emailed Dr. Brisken again, following up about my previous email regarding an interview
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10 November 2014
Writing, UN Library
• Continued writing the failures of chemotherapy section of my paper
• Received a reply from Dr. Brisken, proposing an interview on 14 November 2014 at the
Starbucks near the Lausanne train station, at 17.00

11 November 2014
Writing, UN Library
• Completed draft of the failures of chemotherapy section of my paper
• Began drafting the cancer stem cell hypothesis from a global health perspective section of
my paper

12 November 2014
Personal Interview with Dr. Daniel Constam, EPFL, 14.00-14.20
• Added information from this interview to my section on CSC-targeting therapies

13 November 2014
Phone interview with Dr. Patrick Gaines, 20.00-21.00
• Added information from this interview to my section on CSC-targeting therapies, as well as
my section on the CSC hypothesis from a global health perspective

14 November 2014
Seminar: Regulation of metabolism to allow tumor growth, EPFL, 10.00, conducted by Matthew
vander Heiden, MIT, The Koch Institute for Integrative Cancer Research, hosted by Etienne Meylan
• This seminar didn’t directly address my topic, but it gave me valuable insight into
mechanisms of tumor growth
Personal interview with Dr. Cathrin Brisken, Starbucks Lausanne, 17.15-17.45
• Added information from this interview to my section on CSC-targeting therapies

17 November 2014
Editing, UN Library
• Compiled all sections of paper
• Wrote conclusion, finalized bibliography

18 November 2014
Final editing of paper
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Interviews
Dr. Joerg Huelsken
École Polytechnique Fédérale de Lausanne
3 November 2014
1. Which cell signaling pathways have you worked with as potential drug agent targets in CSCs?
I work with the Wnt gene family, which are involved in controlling cell growth and differentiation.
2. How does this cell signaling pathway in CSCs vary from that in normal cells?
We have found that genes that encode this pathway are mutated in cancer cells, indicating that
mutations can cause healthy stem cells to become cancerous stem cells.
3. When developing drugs that could potentially destroy CSCs via the Wnt pathway, how do you
avoid damaging healthy cells?
This is one of the biggest challenges in CSC research. CSCs share many characteristics with healthy
cells, making systemic delivery of drugs challenging. Certain drug delivery methods, such as
nanoparticle delivery, have shown promise in reducing toxicity. However, systemic delivery is
possible if treatment is individualized and specific mutations in the Wnt pathway are identified.
4. How does the CSC hypothesis illustrate the interaction between public health and medicine?
CSC-targeted drugs show potential in eliminating toxic side effects and impact public health.
Currently, many patients are hospitalized due to toxicity from chemo or radiotherapy, indicating a
need for less harsh cancer pharmaceuticals.
5. How would such a dramatic shift as cancer treatments heavily reliant on chemotherapy to
treatments that target CSCs happen in a reasonable amount of time?
Right now a lot of the research on CSCs is still being done in the lab. We have seen Phase I and II
clinical trials happening, which have shown promise in reducing relapse rates. We need to see more
of these types of trials and get these drugs on the market for use in common practice. One barrier
faced is the incentive for pharma companies to continue developing chemotherapeutic agents,
because they profit from the sale of such drugs.

Dr. Freddy Radtke
École Polytechnique Fédérale de Lausanne
5 November 2014
1. How does an understanding of cellular mechanisms of normal stem cell differentiation help us
better understand CSCs?
Self-renewing cellular systems are continually differentiating from stem cell reservoirs, similar to
how bulk tumor cells differentiate from CSCs.
2. How do the processes of self-renewal and differentiation in CSCs vary from those of normal stem
cells?
In normal stem cells, these processes are tightly regulated. Differentiated cells are only produced
from stem cells when there is a need for them. However, in CSCs, the cell signaling processes are less
regulated because of mutations, disrupting homeostasis.
3. What cell signaling pathways in CSCs have you focused on?
We focus on the Notch signaling pathway in CSCs.
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4. How could targeting CSCs with drugs impact the field of Global Health?
There are several ways. Once we develop drugs that successfully destroy CSCs, the risk of relapse is
essentially zero. Same with metastasis. This would dramatically reduce healthcare costs, as
subsequent rounds of chemotherapy after the first fails are costly and often unsuccessful. Also, when
you reduce deaths, you reduce the burden cancer has on the economy; you don’t lose the economic
productivity of the person who has just passed away.

Dr. Daniel Constam
École Polytechnique Fédérale de Lausanne
12 November 2014
1. How does the Wnt signaling pathway impact CSC tumorigenesis?
Mutations in Wnt can create pro-differentiation signals, meaning that CSCs proliferate, while
programmed cell death is downregulated
2. Why is it important to study such cell signaling pathways?
They have a lot of potential for drug therapy targets, and if they are effectively and specifically
targeted, CSCs can be destroyed. Without CSCs, tumorigenesis is impossible.
3. What is the biggest problem of chemotherapy, in your opinion?
It doesn’t target cancer stem cells. It’s like removing the tip of the iceberg, while there is something
much more dangerous beneath. Chemotherapy makes CSCs more dangerous by selecting for the most
drug-resistant, tumorigenic ones.

Patrick Gaines
Phone Interview
13 November 2014
1. What are some of the clinical trials of cancer stem cell-targeting drugs that you have been involved
with/overseen?
We have worked with hedgehog pathway inhibitors, Wnt inhibitors, and Notch inhibitors. These are
pathways that are thought to be relied upon by CSCs.
2. Were the side effects of these drugs significant, and how do they compare to chemotherapy side
effects?
Targeted therapies are generally better tolerated than chemotherapy. One of our first patients who
received the Wnt inhibitor is now four years in remission from a stage 4 diagnosis without any side
effects.
3. From what you have seen, which drug delivery methods that show promise for delivering CSCtargeting drugs to tumor sites (nanoparticle delivery, etc.)?
Systemic administration is required to get to all potential metastatic sites.
4. What are some of the challenges faced in developing therapies that target cancer stem cells?
Showing that the effect is cCSC-specific, and not just affecting generically all cells
5. Theoretically, what would the public health implications of widespread clinical use of CSCtargeting drugs be (given they are effective at destroying CSCs)? For example, how could lower rates
of drug resistance among cancer patients positively impact populations?

The End of an Era

Paton 49

Putative CSC therapies are being tested in combination with chemotherapy to decrease resistance.
This would decrease toxicity and increase efficacy, thus prolonging life and avoiding admissions from
toxicity.

Dr. Cathrin Brisken
Starbucks Lausanne
14 November 2014.
1. What are some of the CSC-targeting therapies that have proven effective (in clinical trials) in
destroying breast cancer stem cells?
This question is not in my field, as I work with female sex hormones and carcinogenesis, but these
hormones impact cell signaling abilities of CSCs.
2. Why is it important to use living organisms in your research, rather than do experiments in vitro?
There are so many types of breast tissue, and they cannot all be replicated in the lab.
3. How have chemotherapy and radiotherapy been ineffective in the treatment of breast cancer?
They don’t address the underlying problem of cancer; they just eliminate side effects of a deeper
problem (CSCs, hormones, etc.). Radiotherapy for other types of cancer can actually cause mutations
and lead to breast cancer later down the road.
4. Why should doctors switch to a more targeted approach to cancer?
Cancer is such an individual disease, and treatment varies so much from person to person. Signatures
of different types of cancer have been identified that chemo and radiation do not address. They also
have horrible side effects that could be eliminated with treatments that are directed to CSCs.

